Download MendeleyDesign and Optimization of Benzopiperazines as Potent Inhibitors of BET Bromodomains.
Millan, D.S., Kayser-Bricker, K.J., Martin, M.W., Talbot, A.C., Schiller, S.E.R., Herbertz, T., Williams, G.L., Luke, G.P., Hubbs, S., Alvarez Morales, M.A., Cardillo, D., Troccolo, P., Mendes, R.L., McKinnon, C.(2017) ACS Med Chem Lett 8: 847-852
- PubMed: 28835800
- DOI: https://doi.org/10.1021/acsmedchemlett.7b00191
- Primary Citation of Related Structures:
5VOM - PubMed Abstract:
A protein structure-guided drug design approach was employed to develop small molecule inhibitors of the BET family of bromodomains that were distinct from the known (+)-JQ1 scaffold class. These efforts led to the identification of a series of substituted benzopiperazines with structural features that enable interactions with many of the affinity-driving regions of the bromodomain binding site. Lipophilic efficiency was a guiding principle in improving binding affinity alongside drug-like physicochemical properties that are commensurate with oral bioavailability. Derived from this series was tool compound FT001 , which displayed potent biochemical and cellular activity, translating to excellent in vivo activity in a mouse xenograft model (MV-4-11).
Organizational Affiliation:
FORMA Therapeutics Inc., 500 Arsenal Street, Suite 100, Watertown, Massachusetts 02472, United States.
